Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases... Show more
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Momentum Indicator moved below the 0 level on May 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ASPHF as a result. In of 9 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ASPHF turned negative on May 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at .
ASPHF moved below its 50-day moving average on May 15, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ASPHF crossed bearishly below the 50-day moving average on May 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 6 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Industry Biotechnology